A highly innovative Swiss biotech company developing next-gen exosome-based vectors for precise, targeted therapeutic delivery, with applications ranging from cancer treatment to gene therapy.
Enabling breakthrough medicines achieve the outcomes they were designed for. We unlock the full therapeutic potential of innovative drug candidates through our next-generation nanomedicine delivery platform. We transform today’s innovations into tomorrow’s cures by de-risking clinical programs and amplifying therapeutic impact for patients. We want to establish our biovectors as the universal standard for targeted therapeutic delivery.
